The drug services firm Bachem Group has won two contracts for large-scale peptide production that it expects to be worth $26 million in 2023 and $156 million in 2024. Manufacturing will take place ...

The demand for peptides as active pharmaceutical ingredients (APIs) is continuously increasing because they are highly active, highly specific, and metabolically favorable substances. Peptides perform ...

Bachem has signed an agreement to supply large volumes of peptides to an undisclosed customer. Manufacturing will primarily take place at the company’s large-scale production facility currently under ...

To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/10552/288241_figure1.png Anne-Kathrin Stoller, new CEO of Bachem, on ...

Group sales rise to CHF 605.3 million (+4.8%) in 2024. EBITDA increases to CHF 176.3 million (+5.7%). EBITDA margin lies at 29.1%. In local currencies sales rise by 5.6% and EBITDA increases by 7.7% ...

ImmuPharma PLC (AIM:IMM, FRA:25I), the drug discovery and development company, has appointed Swiss manufacturer Bachem to ...

Bubendorf, Switzerland--(Newsfile Corp. - October 23, 2025) - Bachem, a leading partner in peptide and oligonucleotide manufacturing, today announced progress in its plans to expand capacity. In ...

Drugs Already on the Market and in Clinical Studies Drive Novel Method Development Peptides are an emerging class of drugs, somewhere between a small molecule and a biologic. Their synthesis can be ...

Bubendorf, Switzerland--(Newsfile Corp. - May 5, 2026) - Bachem Holding AG (SIX: BANB) ("Bachem") today announced that Torsten Wöhr, Chief Commercial Officer, has decided to pursue a new opportunity ...